Do you have any questions?
Don't hesitate to contact us. We are happy to answer your questions.
Meet us at the 16th meeting of the Asian Cellular Therapy Organization (ACTO)
Meet our medical team to find out more about our clinical program and CAR-T therapies this August 14-16 in Singapore
Meet us at the 16th meeting of the Asian Cellular Therapy Organization (ACTO)
Meet our medical team to find out more about our clinical program and CAR-T therapies this August 14-16 in Singapore
Join our Advances in CAR-T Cell Therapy: APAC Perspectives and Clinical Innovations luncheon seminar at ACTO
Please join us at 12:50 to 13:50 on Thursday August 14 at The Ngee Ann Kongsi (NAK) Auditorium, Academia, Singapore General Hospital Campus
Agenda
12:50 – 12:55: Opening Remarks and Welcome
12:55 – 13:20: Zamtocabtagene Autoleucel (Zamto-cel): Global and APAC Developments and Insights
Dr. Linda Hanssens
13:20 – 13:40: Innovative Approaches in CAR-T Cell Programs in China and Singapore
Professor Leung Wing Hang
12:40 – 12:50: Clinical Insights and Experiences with CAR-T Therapies
Professor Mickey B. C. Koh
12:50 – 13:00: Interactive Q&A Session
We are looking forward to seeing you at ACTO 2025
We look forward to welcoming you to our booth, where you will be able to speak to our medical team about our clinical program and open trials.
ACTO 2025 will take place at Academia, Singapore General Hospital Campus.. You will find us at the Miltenyi Biomedicine booth.
Latest resources from Miltenyi Biomedicine
View recent posters, presentations and press releases
Tandem CD20-CD19-Directed Non-Cryopreserved CAR T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma - Interim Results from a Phase 2 Pivotal Study (DALY II USA)
Tandem Meetings – Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR | presentation slides
Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (zamto-cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma
ASH24 | presentation slides
Miltenyi Biomedicine will share positive interim results from DALY II USA at the American Society of Hematology (ASH) Annual Meeting
ASH 2024 | press release
Bispecific anti-CD20/19 CAR-T – zamtocabtagene autoleucel for relapsed/refractory DLCBL – interim analysis results of DALY-II-USA study
EHA2023 Hybrid Congress | poster information
Interim analysis of a Phase II study of administered fresh bispecific anti-CD20/anti-CD19 CAR T cell therapy zamtocabtagene autoleucel (zamto-cel) for relapsed/refractory (R/R) DLBCL (DALY II USA, NCT04792489)
Tandem Meetings of ASTCT and CIBMTR 2023 I presentation slides
PHASE I TRIAL OF MB-CART2019.1 IN PATIENTS WITH RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA
EHA 2022 | poster download
Characterization and T-Cell Repertoire of MB-CART2019.1 (Zamtocabtagene autoleucel) - Data from the Phase I Trial
ASH 2022 | presentation abstract
Healthcare Resource Utilization and Associated Costs of German Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
ASH 2022 | presentation abstract
Survival Patients Newly Diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL) - Real World Evidence from Germany
ASH 2022 | presentation abstract
